Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn’s Perianal Fistulae

By sjmartinez • August 5, 2023

Maas L, Gao R, Cusumano V, Spartz E, Chowdhury R, Krishna M, Lazarev M, Melia J, Selaru F, Sharma S, Limketkai B, Parian A. Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn's Perianal Fistulae. Dig Dis Sci. 2023 Aug 4. doi: 10.1007/s10620-023-08060-7. Epub ahead of print. PMID: 37540392.

Tags: Crohn’s disease, Digestive Diseases, General Internal Medicine, inflammatory bowel disease, Perianal disease, Perianal fistula, Publications, Resident, Tumor necrosis factor inhibitor

Related Posts

Secondary Spontaneous Bacterial Peritonitis Prophylaxis Is Associated With a Higher Rate of Infections other than Spontaneous Bacterial Peritonitis in 2 US-Based National Cirrhosis Cohorts

Silvey S, Patel N, O'Leary JG, Jakab SS, Patton H, Rogal S, Markley JD, Cheung R, Patel A, Morgan TR, Bajaj JS. Secondary Spontaneous Bacterial[...]

Widespread Pain Moderates the Response to Centrally-Acting Therapies in an Observational Cohort of Patients With Urologic Chronic Pelvic Pain Syndrome: A MAPP Research Network Study

Schrepf A, Locke K, Moldwin R, Williams DA, Till S, Farrar J, Richard Landis J, Tu F, Rodriguez L, Lai H, Naliboff B, Kutch J,[...]

The 2024 top 10 list of endoscopy topics in medical publishing: an annual review by the American Society for Gastrointestinal Endoscopy Editorial Board

Martinez M, Bartel MJ, Chua T, Dakhoul L, Fatima H, Glessing B, Jensen D, Lara LF, Shinn B, Tadros M, Villa E, Saltzman JR. The[...]